Table of Contents
- 1. Product Overview & Specifications
- 2. Key Applications & Research Uses
- 3. Usage Guidelines & Protocols
- 4. Client Case Studies
- 5. Request Customized Solutions
1. Product Overview & Specifications
| Parameter | MRT67307 (CAS 1190378-57-4) | Comparable Inhibitors |
|---|---|---|
| Chemical Name | 8-(6-Phenylhexyl)-2-(2-propen-1-yl)-1,3,8-triazaspiro[4.5]decan-4-one | Amlexanox, BX795 |
| Molecular Formula | C23H33N3O | Varies by compound |
| Molecular Weight | 367.53 g/mol | 268.27 g/mol (Amlexanox) |
| Targets | TBK1/IKKε (IC50 = 19 nM/160 nM) | IKKε/TBK1 (Amlexanox IC50 = 1.8 μM/8.8 μM) |
| Solubility | DMSO: 30 mg/mL, Water: <0.1 mg/mL | DMSO-soluble standard |
| Storage | -20°C, desiccated | Similar storage conditions |
2. Key Applications & Research Uses
Core Research Applications:
- Inhibition of IRF3 phosphorylation in innate immunity studies
- Selective suppression of IFN-β production in viral infection models
- Investigation of autophagy regulation pathways
- Metabolic disease research through TBK1/IKKε pathway modulation
Technical Advantages:
- 10x greater selectivity for TBK1 vs. IKKε compared to earlier inhibitors
- Effective in primary cell cultures at 1-10 μM concentrations
- Minimal off-target effects on related kinases (IKKα/β, JNK, p38)
3. Usage Guidelines & Protocols
Standard Experimental Protocol:
- Prepare stock solution in DMSO at 10 mM concentration
- Dilute in culture medium to final concentration (1-10 μM typical)
- Treat cells for 4-24 hours depending on experimental design
- Combine with viral infection (e.g., HSV-1) or cytokine stimulation
Optimization Tips:
- Pre-test cytotoxicity using MTT assay (recommended range: 0.1-50 μM)
- Combine with IFN-β ELISA for pathway validation
- Use fresh DMSO stocks to prevent compound degradation
4. Client Case Studies
Case Study 1: Virology Research Group
- Client: University of Medical Sciences, Europe
- Application: HSV-1 antiviral mechanism investigation
- Result: 78% reduction in viral replication at 5 μM concentration
- Protocol: 8-hour pre-treatment + 24h post-infection analysis
Case Study 2: Oncology Drug Development
- Client: BioPharma Solutions Inc., USA
- Application: NSCLC combination therapy screening
- Result: Synergy with PD-1 inhibitors (CI=0.62 at 3 μM)
- Outcome: Phase II trial candidate selection
5. Request Customized Solutions
For bulk orders or formulation optimization:
- Email: info@vivalr.com
- Phone: (86) 15866781826
Technical support available for:
- Custom concentration formulations
- GMP-grade production batches
- Stability testing documentation



评论
目前还没有评论。